Metabolic Syndrome Clinical Trial
Official title:
Open-Label Non-Comparative Study of the Effects of a Combination Antihypertensive Treatment With Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome
The aim of study is to assess the angioprotective effects of antihypertensive combination
therapy with perindopril 10 mg and moxonidine 0.4-0.6 mg in patients with arterial
hypertension, metabolic syndrome, and obesity, who had Pulse Wave Velocity (PWV) > 10 m/s on
the previously administered two-component combination antihypertensive therapy.
Open-label non-comparative prospective study for 24 week for each patient.
According to European Society of Cardiology (ESC) and the European Society of Hypertension
(ESH) Guidelines for the management of arterial hypertension 2018 in case of previous
combination at full dose does not allow to achieve the target Blood Pressure (BP), that
therapy might be switch to different two-drug combination.
The study will enroll 120 hypertensive (Grade 1, 2 Arterial Hypertension (AH): Systolic Blood
Pressure (SBP) 140-179 mm Hg and Diastolic Blood Pressure (DBP) 90-109 mm Hg According to
ESC/ESH Guidelines 2018) patients with metabolic syndrome who met the inclusion criteria when
treated with Angiotensin Converting Enzyme Inhibition(ACEi) /Angiotensin Receptor Blocker
(ARB) + hydrochlorothiazide (HCTZ)/indapamide or +amlodipine (30 patients in each group):
1. ACEi (except perindopril) + diuretic (HCTZ or indapamide)
2. ACEi (except perindopril) + amlodipine
3. ARB+ diuretic (HCTZ or indapamide)
4. ARB+ amlodipine
Upon obtaining Inform Consent the previous therapy will be discontinued according to
recommendations (gradually or at once).
After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be
prescribed.
If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg
+ moxonidine 0.6 mg a day (given as two divided doses).
FORBIDDEN TREATMENTS:
Any other antihypertensives (calcium antagonists, β-blockers, ACEi except perindopril, ARBs,
diuretics) for routine AH management (except those used to resolve the uncontrolled
hypertension).
CRITERIA FOR PREMATURE PATIENT WITHDRAWAL FROM THE STUDY:
1. Withdrawal of informed consent by the patient at any time of the study.
2. Need for uncontrolled hypertension management occurring more than 2 times weekly
throughout the 2 consecutive weeks during study period.
3. Need for the third antihypertensive drug.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04635202 -
Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome
|
N/A | |
Completed |
NCT04053686 -
An Intervention to Reduce Prolonged Sitting in Police Staff
|
N/A | |
Completed |
NCT05343858 -
Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Recruiting |
NCT05040958 -
Carotid Atherosclerotic Plaque Load and Neck Circumference
|
||
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Completed |
NCT03289897 -
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
|
N/A | |
Recruiting |
NCT05956886 -
Sleep Chatbot Intervention for Emerging Black/African American Adults
|
N/A | |
Completed |
NCT06057896 -
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
|
||
Active, not recruiting |
NCT03613740 -
Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
|
Phase 2 | |
Completed |
NCT04498455 -
Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency
|
Phase 4 | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03697382 -
Effect of Daily Steps on Fat Metabolism
|
N/A | |
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT04509206 -
Virtual Teaching Kitchen
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A |